Endometrial carcinoma (EC) is a common malignant tumor of the female reproductive system worldwide, and approximately 80% of newly diagnosed EC patients are in the early stage (International Federation of Gynecology and Obstetrics (FIGO) stage IA, IB).1 The TP53 is an important suppressor gene that is deeply involved in tumorigenesis and can control cell growth, apoptosis and regulate angiogenesis. This evidence concerns the gene TP53 and endometrial carcinoma.